ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
10 announcements with these filters
Solara Active Pharma Sciences Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026. This disclosure details equity ownership across various investor categories.
Solara delivered its best profitability in five years despite ongoing Ibuprofen pricing and raw material challenges.
Solara's Q2 FY27 delivered record EBITDA and PAT in five years, driven by 33% revenue growth. Base business strength offset Ibuprofen headwinds, which is now nearing breakeven.
Solara Active Pharma Sciences Limited allotted 8,300 equity shares under its 2018 ESOP plan. The exercise of these options realized Rs. 0.31 Crore for the company.
Solara Active Pharma Sciences Ltd reported revenue from operations of ₹417.3 Cr (+33.1% YoY) and net profit of ₹28.5 Cr for Q2 FY27.
Solara Active Pharma received an ESG rating of 63 ('Strong' category) from Crisil ESG Ratings for the fiscal year 2026, an upgrade from the prior year.
Solara Active Pharma Sciences will issue a Final Reminder-cum-Forfeiture Notice to holders of partly paid-up rights equity shares regarding outstanding call money payments.
Solara Active Pharma Sciences Ltd has scheduled a board meeting on October 16, 2026, to consider and approve the financial results for the period ended September 30, 2026.
Solara Active Pharma Sciences is notifying physical shareholders to update their PAN, KYC, and nomination details per SEBI circulars. This is a routine regulatory compliance intimation.
Solara Active Pharma Sciences Limited held its Ninth Annual General Meeting on September 18, 2026. Shareholders transacted business, including approving related party transactions.